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6/j.bSingle nucleotide polymorphisms (SNPs) in the innate immunity receptor NOD2/CARD15 have been dem-
onstrated to modulate the outcome of allogeneic hematopoietic stem cell transplantation (SCT). The effect
of NOD2/CARD15 polymorphism is reported to be associated with type of donor (sibling or matched un-
related donor) as well as type of conditioning regimen. We reviewed NOD2/CARD15 SNPs in all donor/re-
cipient pairs of 192 consecutive patients who received nonmyeloablative allogeneic SCT at our institution
between 2002 and 2006. All patients were treated with fludarabine 30 mg/m2/day for 3 days followed by
200 cGy total-body irradiation (TBI) (n 5 154) or TBI alone (n 5 38) and received grafts from HLA-
matched related (n5 132) or unrelated (n5 61) donors. NOD2/CARD15 polymorphisms were observed
in 36 of 192 (19%) patients and in 35 of 192 (18%) donors. The incidences of acute and chronic graft-versus-
host disease (aGVHD, cGVHD) were 39% and 49%, respectively, in patients with NOD2/CARD15 variants
versus 51% and 61% in patients with wild type. The relapse rate at 3 years was 38% in patients with variants
and 36% in patients with wild type. The incidence of transplant-related mortality was 22% for patients with
variants and 21% for patients with wild type. Overall survival (OS) at 3 years was 56% in patients with variants
and 64% in patients with wild-type NOD2/CARD15. There was no significant impact of NOD2/CARD15
mutations on clinical outcome (all P . .05, Kaplan-Meier and Fine and Gray’s tests). These data indicate
that mutations in the NOD2/CARD15 gene are not a risk factor for clinical outcome in nonmyeloablative
allogeneic SCT. Therefore, screening for NOD2/CARD15 polymorphisms in patients or donors does not
have additional value in patients undergoing nonmyeloablative SCT.
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.00
bmt.2010.12.709NOD2/CARD15 is an intracellular microbial sensor
mostly present in macrophages, dendritic cells, and
bronchial as well as intestinal epithelial cells, including
Paneth cells. The importance of the NOD2/CARD15
genewas first appreciated by its identification as a locus
linked to Crohn’s disease. Single nucleotide polymor-
phisms (SNPs) within the gene were associated with an
increased susceptibility to Crohn’s disease and with
functional defects [1,2]. The exact pathogenesis is
not yet fully understood and remains controversial.
Loss of antimicrobial activity and deregulated
immune response are the suggested hypotheses [3-5].
Recently, several studies have shown an association
between the presence of 3 SNPs in the NOD2/
CARD15 gene and the outcome of allogeneic hemato-
poietic stem cell transplantation (SCT). The vast
majority of these studies, but not all, have shown unfa-
vorable effects by the presence of SNPs (NOD2/
CARD15 variants) on the incidence of acute graft-
versus-host disease (aGVHD), relapse rate, and1231
1232 Biol Blood Marrow Transplant 17:1231-1236, 2011H. M. van der Straaten et al.treatment-related mortalilty (TRM), as well as a
relationship with the development of bronchiolitis ob-
literans. The effect seems to be associated with type of
donor (sibling or matched unrelated donor) as well as
type of conditioning regimen and gastrointestinal de-
contamination [6-14].
We analyzed the impact of NOD2/CARD15 poly-
morphisms in a large cohort of 192 consecutive pa-
tients who received a nonmyeloablative allogeneic
SCT at our institution.
PATIENTS AND METHODS
Patients and Donors
The study group consisted of 198 patients who un-
derwent a nonmyeloablative allogeneic SCT at the
University Medical Center of Utrecht between Sep-
tember 2001 and June 2006. Six patients were excluded
because of nonengraftment or missing DNA samples.
Table 1 summarizes patient and donor characteristics.
Patients gave informed consent and were treated ac-
cording to the clinical protocols approved by the local
ethics review board.
SCT Procedure
The nonmyeloablative conditioning regimen
consisted of fludarabine 30 mg/m2/day for 3 days)Table 1. Patient and Donor Characteristics
Variable
Recipient and
Donor WT
N 5 131
Recipient
and/or
Donor SNP
N 5 61
Age, years (Recipient)
Median 58 59
Range 20-73 22-72
Sex, male
Recipient, % (n) 63 (83) 66 (40)
Diagnosis
Acute lymphoblastic leukemia, % (n) 6 (8) 2 (1)
Acute myeloid leukemia/MDS, % (n) 21 (28) 31 (19)
CML/Myeloproliferative disorder, % (n) 4 (5) 7 (4)
Lymphoma (CLL, NHL)/MM, % (n) 60 (79) 48 (29)
Other,* % (n) 8 (11) 13 (8)
Disease stage
Low-risk, % (n) 27 (36) 31 (19)
High-risk, % (n) 73 (95) 69 (42)
HLA matching
HLA-identical sibling, % (n) 68 (89) 56 (34)
Matched unrelated donor, % (n) 27 (36) 41 (25)
Partially matched related donor, % (n) 5 (6) 3 (2)
Conditioning regimen
TBI, % (n) 25 (33) 8 (5)
Fludarabine/TBI, % (n) 37 (49) 41 (25)
ATG/Fludarabine/TBI, % (n) 37 (49) 51 (31)
WT indicates wild type; MDS, myelodysplastic syndrome; CML, chronic
myelogenous leukemia; CLL, chronic lymphocytic leukemia; NHL, non-
Hodgkin lymphoma; MM, multiple myeloma; ATG, anti-thymocyte glob-
ulin; TBI, total-body irradiation.
Low-risk: patients with acute leukemia in first complete remission,
chronic myelogenous leukemia in first chronic phase and untreated se-
vere aplastic anemia.
High-risk: all other haematologic diseases.
*Severe aplastic anemia, amyloidosis, hypereosinophilic syndromefollowed by total-body irradiation (TBI) of 200 cGy
(n5 154) or 200 cGy TBI alone (n5 38). The (unma-
nipulated) graft was infused after TBI on day 0. In re-
cipients of a histocompatibility leukocyte antigen
(HLA)-matched unrelated donor (MUD) or a single
HLA-antigen mismatched family donor, anti-thymo-
cyte globulin (Rabbit ATG, Thymoglobulin, Gen-
zyme, Cambridge, MA) was given before fludarabine,
at a dose of 2 mg/kg/day for 4 days (n 5 61).
All patients received oral GVHD prophylaxis with
cyclosporine and mycophenolate mofetil (MMF). Cy-
closporine was started on day 23 at 4.5 mg/kg twice
daily and continued at least until day 184, followed
by tapering if no GVHD was present. Dose adjust-
ments were made to keep cyclosporine trough levels
between 200 ng/mL and 400 ng/mL.MMFwas started
5 hours after graft infusion at 45 mg/kg/day with
a maximum dose of 3 g/day until day128 or1 84, fol-
lowed by tapering if no GVHD was present. Infection
prevention consisted of ciprofloxacin and fluconazole,
given orally, until granulocyte counts exceeded 500
cells/mL. Of note, as generally very few patients had
a decrease in granulocytes below 500/mL, this infec-
tion prevention was of short duration. Cotrimoxazole
480 mg twice daily was given for 15 months, and vala-
cyclovir 500 mg twice daily was given for 12 months,
both orally.Typing for NOD2/CARD15 SNPs
For sequence-based typing (SBT) analysis, SNP8
(Arg702Trp), SNP12 (Gly908Arg), and SNP13
(Leu1007fsinsC) of the NOD2/CARD15 gene were
amplified in 1 polymerase chain reaction (PCR) on
the GeneAmp PCR system 7900 (Applied Biosystems,
Foster City, CA). The PCR mixture for amplification
of these polymorphic sites consisted of 2.5 mL of
10 PCR buffer, 1.5 mL of 25 mM MgCl2, 1.5 mL of
10 mM dNTPs (all from Applied Biosystems), 0.25
mL of 10 pmol/mL SNP8 forward and reverse amplifi-
cation primers, and 0.5 mL of 10 pmol/mL forward and
reverse primers of SNP12 and -13 (Sigma Aldrich
Company, St. Louis, MO), 15.0 mL of MQ, 0.5 mL
of Taq Gold (Applied Biosystems), and 2 mL of
DNA (100 ng/mL). The amplification primers are
shown in Table 2. The PCR was performed with the
following thermocycling program: 10 minutes 95C,
followed by 35 cycles of 30 seconds at 94C, 30 sec-
onds at 58C, and 30 seconds at 72C.
After PCR, the amplification products were puri-
fied with 0.5 mL of exonuclease I (20,000 U/mL)
(New England Biolabs, Beverly, MA) and 1 mL of
shrimp alkaline phosphatase (1 U/mL) (United States
Biochemical, Staufen, Germany). Purified amplifica-
tion products were sequenced with the specific ampli-
fication primers (Table 2) and the Big Dye Terminator
Kit according to manufacturer’s guidelines (Applied
Table 2. Primers for Amplification and Sequencing of SNP8, -12, and -13 of the NOD2/CARD15 Gene
NOD2/CARD15 Primers for Amplification and Sequencing
SNP Direction Location Coverage Sequence (50/ 30)
8 Forward Exon 4 Part of exon 4 GCAGGCCAGGCAACTCACCA
Reverse Exon 4 CAAAGGCCAGGGCAGCA
12 Forward Intron 7 Exon 8 AAGCGTATCTGAACTAAGTGTC
Reverse Intron 8 CAAGTCACCCAGAAAGACTC
13 Forward Intron 10 Exon 11 GAGCAGGATGTGTCTAAGGGA
Reverse Intron 11 CAGAATCATTCTCACTGAATGTC
Biol Blood Marrow Transplant 17:1231-1236, 2011 1233No Impact of NOD2/CARD15 after NMA allo-SCTBiosystems), on the 3130  L Genetic Analyzer (Ap-
plied Biosystems).
Statistical Analysis
Kaplan-Meier survival curves were made for over-
all survival (OS) and compared by log-rank test.
Cumulative incidence of GVHD, TRM, and relapse
rate was calculated by competing risk analysis and
comparisons between the groups made by the Fine
and Gray’s test. The incidence of GVHD and relapse
were estimated by cumulative incidence analysis con-
sidering death as competing event. Death not related
to TRM was considered the competing event for
TRM. Analyses were performed using SPSS version
15.0 (SPSS Inc., Chicago, IL) or the R package cmprsk
[15]. All P values were 2 sided, and a value of\.05 was
considered statistically significant.RESULTS
Frequency of NOD2/CARD15 SNPs
NOD2/CARD15 variants were observed in 36 of
192 (19%) patients and in 35 of 192 (18%) donors
(Table 3), similar to the general Dutch population
[16]. The frequencies of the individual SNPs were
comparable in donors and patients. There were 11
donor-patients pairs (6%) in whom the polymorphism
occurred in both individuals. One donor (0.5%) car-
ried 2 different mutations. We found 9 cases (5%) of
homozygosity.Table 3. Frequency of SNPs in Donor/Recipient Pairs
Donor/Recipient Relationship Pair N 5 192
WT donor/WTrecipient 131
SNP donor/WTrecipient 24
SNP8/WT 11
SNP12/WT 5
SNP13/WT 7
SNP8 + SNP13/WT 1
SNP recipient/WT donor 26
SNP8/WT 17
SNP12/WT 4
SNP13/WT 5
SNP8/SNP8 5
SNP8/SNP13 1
SNP13/SNP8 1
SNP13/SNP13 4NOD2/CARD15 SNPs and GVHD
The overall incidence of aGVHD grade II-IV
was 46%. The cumulative incidence of aGVHD at 1
year follow-up was 39% in patients with and 51% in
patients without NOD/CARD15 SNPs. There was
no significant difference between the 2 groups (see
Figure 1).
One hundred four of 173 evaluable patients (60%)
developed chronic GVHD. (cGVHD). At 3 years
follow-up, the cumulative incidence of cGVHD was
49% in patients with SNPs and 61% in patients with
the wild type (WT). The difference was not statisti-
cally significant (see Figure 2).NOD2/CARD15 SNPs and Relapse and TRM
Relapse was seen in 37% (71/192) of all patients.
The cumulative incidence at 3 years was 38% in pa-
tients with SNPs versus 36% in wild-type patients
(see Figure 3).
The overall incidence of TRM was 21%. The cu-
mulative incidence of TRM at 3 years follow up was
similar in both groups: 22% in the group with and
21% in the group without SNPs (see Figure 4).Figure 1. Cumulative incidence of aGVHD.
Figure 2. Cumulative incidence of cGVHD. Figure 4. Cumulative incidence of TRM.
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Seventy-eight patients died (41%) at a median time
of 7 (1-47) months. The median time of follow-up for
surviving recipients was 36months, ranging from 16 to
72 months. The estimated 3-years OS was 64% in pa-
tients without and 56% in patients with SNPs of the
NOD2/CARD15 gene (log-rank test on total follow
up period; P 5 .54, see Figure 5).DISCUSSION
Our results show that mutations within the NOD2/
CARD15 gene do not influence the clinical outcome
of nonmyeloablative allogeneic SCT. We did not find
a significant correlation between the presence of
NOD2/CARD15 polymorphisms and the incidenceFigure 3. Cumulative incidence of relapse.of aGVHD, cGHVD, TRM, relapse rate, and OS.
These findings are in contrast to most previous reports
[6,7,9,10,12,17] and confirmed by 2 recent analyses
[13,14]. However, even studies revealing NOD2/
CARD15 variants as a significant indicator of
transplantation outcome lack consistency: some report
that NOD2/CARD15 SNPs are associated with an
increase in relapse [7,12], whereas others demonstrated
an impact on GVHD and TRM [9,10,17].
Most probably, these diverging results are at least
partly explained by differences in the patient cohorts
and treatment that were studied. First of all, the fre-
quency of NOD2/CARD15 SNPs will influence their
prognostic impact. In our study, nearly 20%of patientsFigure 5. Overall Survival.
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line with most other reports and the general Dutch
population [16]. Notably, the 2 previous studies that
did not find an association of NOD2/CARD15 with
transplantation outcome were hampered by a lower in-
cidence of SNPs. Besides, the incidence of aGVHD
was remarkably low in these studies, which might also
have contributed to the lack of correlation [13,14].
Second, results seem to be influenced by the use
and method of T cell depletion. Even among patient
cohorts receiving a T cell–depleted graft, contradic-
tory effects of NOD2/CARD15 SNPs on outcome
data are reported [7,12,17]. The method of T cell
depletion (in vivo or in vitro) was not similar in all
patients, and this might have played an additional
role. Whether T cell depletion is of direct
importance, or influences transplantation outcome
via a decreased incidence of GVHD, remains
unclear. The only study on T cell–depleted allogeneic
SCT that found a detrimental effect of NOD2/
CARD15 mutations on GVHD [17] also reported
a higher incidence of GVHD than the other studies,
underlining that the incidence of GVHD is important
in the possibility to demonstrate associations with pos-
sible prognostic factors. In our analysis, the patients
receiving a graft from a MUD were treated with
ATG as part of the conditioning regimen. However,
in an explorative subgroup analysis, we did not observe
a difference in any of the outcome parameters among
the patients with NOD2/CARD15 SNPs who re-
ceived a sibling graft versus those with a matched un-
related donor (data not shown).
Third, the type and severity of aGVHD might in-
fluence the possible impact of NOD/CARD2 muta-
tions. The incidence of aGVHD grade II-IV in our
study was within the expected range. Eighteen percent
of patients experienced severe (grade III/IV) aGVHD,
which is in line with other studies. Intestinal GVHD
was only present in 8% of patients. This relatively
low percentage of intestinal GVHD might have con-
tributed to the lack of significant correlation observed
in our study. The sample sizes unfortunately did not
allow for more detailed exploration.
Moreover, some authors suggest that the effect of
NOD2/CARD15 SNPs is significant in acute lympho-
blastic leukemia (ALL) patients [12], but absent in
acute myeloid leukemia (AML). The number of ALL
patients in our study was too small to allow any sub-
group analysis.
The variety of diagnoses in our patient cohort
could be considered a confounding variable. The
prime focus of our analysis, however, was to study
a possible impact of a less intensive conditioning regi-
men on the role of NOD2/CARD15 SNPs. Because
our parameter of interest is a genetic variant, we do
not think that patient characteristics, such as underly-
ing disease, will have played a confounding role.Finally, our study is the first that described a uni-
form cohort of patients receiving a nonmyeloablative
conditioning regimen, whereas almost all other studies
reported data on myeloablative conditioning regi-
mens. One previous study included patients receiving
ablative as well as nonablative regimens, and no major
impact on the type of conditioning was observed [10].
Nevertheless, the impact of a less intensive preparative
regimen on the role of NOD2/CARD15 SNPs has not
been explored rigorously before. Because our data on
the incidence of SNPs and overall incidence of
GVHD as well as patient characteristics and infection
prophylaxis are comparable with most previous
studies, the conditioning regimen might well be an
additional factor in determining the impact of
NOD2/CARD15 variants. NOD2/CARD15 SNPs
are associated with an abnormal excess of proinfla-
mmatory cytokine response [3-5]. Nonmyeloablative
conditioning causes less tissue damage in the
recipient, leading to a less profound proinflammatory
milieu. Furthermore, recipients of nonmyeloablative
conditioning regimens generally do not develop
significant granulocytopenia and, consequently, early
serious bacterial infections. The lack of a prolonged
neutropenic period prevents a major impact of
bacterial load on initiation of immune reactions.
Therefore, NOD2/CARD15 SNPs may well be of less
importance in the modulation of events after a
nonmyeloablative preparative regimen.
Taken together, the impact of NOD2/CARD15
SNPs on transplantation outcome is probably influ-
enced by several patient and transplantation characteris-
tics. Identification of these various factors is an
important and ongoing process, in order to establish
non-HLAgenetic factors that contribute to theoutcome
of SCT. The type of conditioning regimen could be an
important factor. BecauseNOD2/CARD15 variants are
not recognized as a single significant prognostic factor,
screening for NOD2/CARD15 polymorphisms when
selecting a donor does not have additional value in pa-
tients undergoing nonmyeloablative SCT.
The SBT method for NOD SNP analysis is sole
proprietary knowledge of Genome Diagnostics BV
Utrecht, The Netherlands. Filing a patent application
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